Comprehensive approach to personalized treatment in pulmonary arterial hypertension

Ali Aminazad
Eastern Health, Victoria, Australia

Areas to be discussed:
Available medications for Pulmonary Hypertension in 2025, how the field has progressed in the last 2 decades.

Updates on drug classes (endothelin receptor antagonists, phosphodiesterase 5 inhibitors, soluble guanylate cyclase stimulators, and prostacyclin analogues/receptor agonists).

Emerging therapies integrated into treatment algorithms.

The choice of treatment- what initial and sequential combination therapy?

Early aggressive treatment: Emphasis on upfront dual or triple oral combination therapy in intermediate-to-high risk patients rather than stepwise escalation. 

Novel agents and pathways: Incorporation of sotatercept (activin signaling modulator) in specific patient populations showing promising outcome benefits.

Refined risk assessment tools: Use of multiparametric scoring (functional class, biomarkers, imaging, and hemodynamics) to guide treatment adjustments.

How Cardiopulmonary Exercise Testing (CPET) can help not only to risk stratify but also, to guide treatment options in PHT 

Risk factor modification and Holistic management: What are the treatments options to address associated risk factors and disease-targeted treatments.

Integration of supportive measures (oxygen therapy, and pulmonary rehabilitation)